| Patent | Date |
|---|
Highly Purified Pharmaceutical Grade Tasimelteon
App 20220073482 - Phadke; Deepak ; et al. | 2022-03-10 |
Liquid tasimelteon formulations and methods of use thereof
Grant 11,202,770 - Phadke , et al. December 21, 2 | 2021-12-21 |
Highly purified pharmaceutical grade tasimelteon
Grant 11,203,581 - Phadke , et al. December 21, 2 | 2021-12-21 |
Liquid Tasimelteon Formulations and Methods of Use Thereof
App 20210212980 - Phadke; Deepak ; et al. | 2021-07-15 |
Liquid Tasimelteon Formulations and Methods of Use Thereof
App 20210177799 - Phadke; Deepak ; et al. | 2021-06-17 |
Iloperidone Metabolite For Use In The Treatment Of Psychiatric Disorders
App 20210015809 - Phadke; Deepak ; et al. | 2021-01-21 |
Highly Purified Pharmaceutical Grade Tasimelteon
App 20210017143 - Phadke; Deepak ; et al. | 2021-01-21 |
Iloperidone metabolite for use in the treatment of psychiatric disorders
Grant 10,874,659 - Phadke , et al. December 29, 2 | 2020-12-29 |
Melatonin Agonist Treatment
App 20200397741 - Birznieks; Gunther P. ; et al. | 2020-12-24 |
Highly purified pharmaceutical grade tasimelteon
Grant 10,829,465 - Phadke , et al. November 10, 2 | 2020-11-10 |
Highly Purified Pharmaceutical Grade Tasimelteon
App 20200190048 - Phadke; Deepak ; et al. | 2020-06-18 |
Highly purified pharmaceutical grade tasimelteon
Grant 10,611,744 - Phadke , et al. | 2020-04-07 |
Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanami- de
Grant 10,233,142 - Dressman , et al. | 2019-03-19 |
Highly Purifid Pharmaceutical Grade Tasimelteon
App 20190002423 - Phadke; Deepak ; et al. | 2019-01-03 |
Highly purifid pharmaceutical grade tasimelteon
Grant 10,071,977 - Phadke , et al. September 11, 2 | 2018-09-11 |
Melatonin Agonist Treatment
App 20180243258 - Birznieks; Gunther P. ; et al. | 2018-08-30 |
Metabolites Of (1r-trans)-n-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanami- De
App 20180099924 - Dressman; Marlene Michelle ; et al. | 2018-04-12 |
Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanami- de
Grant 9,850,199 - Dressman , et al. December 26, 2 | 2017-12-26 |
Highly Purifid Pharmaceutical Grade Tasimelteon
App 20170190683 - PHADKE; Deepak ; et al. | 2017-07-06 |
Metabolites Of (1r-trans)-n-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanami- De
App 20170174617 - Dressman; Marlene Michelle ; et al. | 2017-06-22 |
Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanami- de
Grant 9,617,203 - Dressman , et al. April 11, 2 | 2017-04-11 |
Melatonin Agonist Treatment
App 20160354337 - Birznieks; Gunther ; et al. | 2016-12-08 |
Metabolites Of (1r-trans)-n-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanami- De
App 20160060212 - Dressman; Marlene Michelle ; et al. | 2016-03-03 |
Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanami- de
Grant 9,212,129 - Dressman , et al. December 15, 2 | 2015-12-15 |
Metabolites Of (1r-trans)-n-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanami- De
App 20150148419 - Dressman; Marlene Michelle ; et al. | 2015-05-28 |
Melatonin Agonist Treatment
App 20150080464 - Birznieks; Gunther ; et al. | 2015-03-19 |
Iloperidone Metabolite For Use In The Treatment Of Psychiatric Disorders
App 20150045390 - Phadke; Deepak ; et al. | 2015-02-12 |
Stable dosage formulations of imidazolylalkyl-pyridines
Grant 8,865,210 - Lavedan , et al. October 21, 2 | 2014-10-21 |
Use Of A Melatonin Agonist For The Treatment Of Sleep Disorders Including Primary Insomnia
App 20120136050 - Polymeropoulos; Mihael H. ; et al. | 2012-05-31 |
Treatment For Depressive Disorders
App 20090209638 - Birznieks; Gunther ; et al. | 2009-08-20 |
Melatonin Agonist Treatment
App 20090105333 - Birznieks; Gunther ; et al. | 2009-04-23 |
Stable Dosage Formulations Of Imidazolylalkyl-pyridines
App 20090011011 - Lavedan; Christian N. ; et al. | 2009-01-08 |
| 